期刊文献+

晚期儿童神经母细胞瘤的临床和预后分析 被引量:7

Clinical features and prognosis of advanced neuroblastoma in children
下载PDF
导出
摘要 目的探讨晚期儿童神经母细胞瘤的临床特点、治疗策略和预后。方法对63例确诊为III~IV期的神经母细胞瘤患者的临床资料进行回顾性分析,有60例患者接受了手术切除和(或)化疗和(或)局部放疗,其中14例患者还接受了自体外周血造血干细胞移植治疗。结果63例患者中,男女比例为2.7∶1,中位年龄4岁;常见首发症状为发热、腹痛、腹部肿块、腿痛或关节疼痛;常见原发部位为肾上腺(38%)、腹膜后(35%)、后纵隔(17%)、盆腔(6%)和颈部(2%);确诊时常见转移部位为局部(41%)和(或)远处(37%)淋巴结、骨髓(60%)、骨(46%)、肝脏(16%)。中位生存时间32.7个月,2年生存率44.3%。年龄>1岁(P<0.05)、血清神经元特异性烯醇化酶>100mg/L(P<0.05)、血清乳酸脱氢酶>1500U/L(P<0.01)、血清铁蛋白>150mg/L(P<0.05)是预后不良指标。完整切除原发肿瘤可延长患者总体生存时间(P<0.05);强烈化疗联合自体外周血造血干细胞移植的综合治疗可延长患者总体生存时间(P<0.01)。结论晚期儿童神经母细胞瘤临床表现多样,预后差,熟悉其临床和实验室检查特点尽早明确诊断、完整切除原发肿瘤、进行自体外周血造血干细胞移植支持下的强烈化疗的综合治疗有利于改善预后。 Objective To investigate the clinical features, treatment modalities and the prognosis of advanced neuroblastoma in children. Methods The medical records of 63 children with stage III or IV neuroblastoma from January 1996 to December 2005 were retrospectively reviewed. Sixty patients were treated by tumor resection and (or) chemotherapy and (or) radiation. Fourteen out of the 60 patients received another autologous peripheral blood stem cell transplantation. Results Of the 63 patients with advanced neuroblastoma, the male/female ratio was 2.7:1 and the median age at diagnosis was 4 years old. Most of the initial symptoms included pyrexia, abdominal pain, abdominal mass, and leg or articular pain. Primary tumor sites were adrenal (38%), retroperitoneal (35%), mediastinal (17%), pelvic (6%) and cervical (2%). The sites of metastasis at diagnosis included local (41%) and (or) distant (37%) lymph nodes, bone marrow (60%), bone (46%) and liver ( 16% ). The median survival time of the 63 patients was 32.7 months. The 2-year survival rate was 44.3%. Statistical analysis demonstrated that unfavorable survival prognostic factors were the following: age 〉 1 year at diagnosis (P 〈0.05) ; serum neuro-specific enolase 〉 100 mg/L (P 〈0.05) ; serum lactic dehydrogenase 〉 1 500 U/L (P 〈0. 01 ) ; serum ferritin 〉 150 mg/L (P 〈0.05). The overall survival period of the patients was prolonged through total resection of the primary tumor ( P 〈 0. 05 ). Intensive chemotherapy in combination with autologous peripheral blood stem cell transplantation could also result in a prolonged overall survival period ( P 〈 0.01 ). Conclusions Neuroblastoma with advanced stages often presents with various clinical manifestations and has a poor prognosis. It is beneficial to improve the prognosis of neuroblastoma through an early diagnosis and a comprehensive therapy including total resection of the primary tumor, autologous peripheral blood stem cell transplantation and intensive chemotherapy.
出处 《中国当代儿科杂志》 CAS CSCD 2007年第4期351-354,共4页 Chinese Journal of Contemporary Pediatrics
关键词 神经母细胞瘤 治疗 预后 儿童 Neuroblastoma Therapy Prognosis Child
  • 相关文献

参考文献9

  • 1唐锁勤.神经母细胞瘤的诊断及治疗[J].实用儿科临床杂志,2005,20(1):4-6. 被引量:21
  • 2Brodeur GM,Seeger RC,Barrett A,Berthold F,Castleberry RP,D'Angio G,et al.International criteria for diagnosis,staging,and response to treatment in patients with neuroblastoma[J].J Clin Oncol,1988,6(12):1874-1881.
  • 3Grosfeld JL.Risk-based management of solid tumors in children[J].AmJ Surg,2000,180(5):322-327.
  • 4Shimada H,Ambros IM,Dehner LP,Hata J,Joshi VV,Roald B,et al.The international neuroblastoma pathology classification(the Shimada system)[J].Cancer,1999,86(2):364-372.
  • 5王亚柱,李强,张锦华,段树德,郭兑山,张海鹏.高效液相色谱法检测尿中儿茶酚胺代谢产物含量在神经母细胞瘤早期诊断中的价值[J].中国当代儿科杂志,2004,6(1):34-37. 被引量:11
  • 6La Quaglia MP,Kushner BH,Su W,Heller G,Kramer K,Abramson S,et al.The impact of gross total resection on local control and survival in high-risk neuroblastoma[J].J Pediatr Surg,2004,39(3):412-417.
  • 7Von Schweinitz D,Hero B,Berthold F.The impact of surgical radicality on outcome in childhood neuroblastoma[J].EurJ Pediatr Surg,2002,12(6):402-409.
  • 8Berthold F,Boos J,Burdach S,Erttmann R,Henze G,Hermann J,et al.Myeloablative megatherapy with autologous stem-cell rescue versus oral maintenance chemotherapy as consolidation treatment in patients with high-risk neuroblastoma:a randomised controlled trial[J].Lancet Oncol,2005,6(9):649-658.
  • 9唐锁勤,黄东生,王建文,冯晨,杨光.大剂量化疗造血干细胞移植治疗IV期神经母细胞瘤的长期疗效研究[J].中国当代儿科杂志,2006,8(2):93-96. 被引量:27

二级参考文献13

  • 1冯晨,唐锁勤,黄东生,王建文,于芳,杨光.CEM为预处理方案的自体外周血造血干细胞移植治疗晚期神经母细胞瘤相关毒性及疗效观察[J].中国当代儿科杂志,2004,6(6):489-491. 被引量:3
  • 2孟庆丰,吴敏,张云霞,岳同云,宋晓时,刘杰,王桂英,孟彤.神经母细胞瘤65例临床分析[J].实用肿瘤学杂志,1995,9(2):61-62. 被引量:2
  • 3⑻锎兢悉.神经芽细胞种の生化学的\断[J].小儿外科.内科,1973,5(7):655-655.
  • 4逆井悦子 望月孝一 高桥典子 真田正美 西田俊朗 山本圭子.琦玉具hにおける神经芽细胞瘤マススクリ`ニング一一次スクリ`ニングの现状と今後 [J].琦玉小儿医疗センタ`医学志,2000,17(2):89-92.
  • 5望月孝一 逆井悦子 西田俊朗.琦玉具における神经芽细胞种マススクリ`ニング [J].琦玉技会志,1998,45(4):241-244.
  • 6佐藤泰昌 福士胜 高杉信男 武田武夫.神经芽细胞种スクリ`ニングにおける尿中VMA、HVA测定值とその判断 [J].日本小儿科学会杂志,1985,89(12):2665-2671.
  • 7Ponthan F,Borgstrom P,Hassan M,Wassberg E,Redfern CP,Kogner P.The vitamin A analogues:13-cis retinoic acid,9-cis retinoic acid and Ro 13-6307 inhibit neuroblasoma tumour growth in vivo[J].Med Pediatr Oncol,2001,36 (1):127-131.
  • 8Reynolds CP,Matthay KK,Villablanca JG,Maurer BJ.Retinoid therapy of high-risk neuroblastoma[J].Cancer Lett,2003,197(1-2):185-192.
  • 9Nagai J,Yazawa T,Okudela K,Kigasawa H,Kitamura H,Osaka H.Retinoic acid induces neuroblastoma cell death by inhibiting proteasomal degradation of retinoic acid receptor alpha[J].Cancer Res,2004,64(21):7910-7917.
  • 10Castel V,Tovar JA,Costa E,Cuadros J,Ruiz A,Rollan V,et al.The role of surgery in stage Ⅳ neuroblastoma[J].J Pediatr Surg,2002,37 (11):1574-1578.

共引文献56

同被引文献58

  • 1王晓戎,李平,吴志丽.肿瘤化疗后中医证候学特征调查研究[J].山东中医杂志,2006,25(1):18-20. 被引量:46
  • 2连海英,张雪林,成官迅,王劲,曾弘,邱士军,林志春.节细胞神经瘤的CT、MRI诊断[J].实用放射学杂志,2006,22(3):281-284. 被引量:23
  • 3唐锁勤,黄东生,王建文,冯晨,杨光.大剂量化疗造血干细胞移植治疗IV期神经母细胞瘤的长期疗效研究[J].中国当代儿科杂志,2006,8(2):93-96. 被引量:27
  • 4汤静燕,潘慈,陈静,徐敏,薛惠良,顾龙君,董茹,叶辉,周敏,王耀平.45例儿童神经母细胞瘤预后因素分析[J].中华儿科杂志,2006,44(10):770-773. 被引量:21
  • 5甄子俊,孙晓非,夏奕,王智辉,凌家瑜.异环磷酰胺联合卡铂治疗复发和难治性神经母细胞瘤的疗效分析[J].癌症,2006,25(12):1550-1552. 被引量:5
  • 6Kaneko M, Tsuchida Y, Mugishima H, Ohnuma N, Yamamoto K, Kawa K, et al. Intensified chemotherapy increases the survival rates in patients with stage 4 neuroblastoma with MYCN amplification[J]. J Pediatr Hematol Oncol, 2002, 24(8) :613-621.
  • 7Kramer K, Kushner BH, Cheung NK. Oral topotecan for refractory and relapsed neuroblastoma: a retrospective analysis [ J ]. J Pediatr Hematol Oncol, 2003, 25(8) :601-605.
  • 8Saylors RL 3rd, Stine KC, Sullivan J, Kepner JL, Wall DA, Bernstein ML, et al. Cyclophosphamide plus topotecan in children with recurrent or refractory solid tumors: a Pediatric Oncology Group phase Ⅱ study [J]. J Clin Oncol, 2001, 19(15) :3463-3469.
  • 9Simon T, Langler A, Berthold F, Klingebiel T, Hero B. Topotecan and etoposide in the treatment of relapsed high-risk neuroblastoma: results of a phase 2 trial[ J ]. J Pediatr Hematol Oncol, 2007, 29(2) :101-106.
  • 10Garaventa A, Luksch R, Biasotti S, Severi G, Pizzitola MR, Viscardi E, et al. A phase II study of topotecan with vincristine and doxorubicin in children with recurrent/refractory neuroblastoma [ J]. Cancer, 2003, 98 ( 11 ) :2488-2494.

引证文献7

二级引证文献32

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部